Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 9.57.
Forward PE Ratio (9.57) = Close Price ($27.79) / Consensus Forward EPS ($2.97)
FORWARD PE RATIO
9.57
SECTOR MEDIAN · HEALTHCARE
20.01
median of 78 covered companies
CURRENT VS SECTOR MEDIAN
-52.17%
vs the sector median at left
Pfizer Inc.
Market Cap
$158.39B
Forward PE Ratio
9.57
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Pfizer Inc. (PFE) | $158.39B | 9.57 |
| Danaher Corporation (DHR)vs › | $144.25B | 24.14 |
| Gilead Sciences, Inc. (GILD)vs › | $182.06B | N/A |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $134.24B | 29.13 |
| Abbott Laboratories (ABT)vs › | $182.59B | 19.13 |
| Bristol-Myers Squibb Company (BMY)vs › | $132.14B | 9.34 |
| Intuitive Surgical, Inc. (ISRG)vs › | $123.70B | 33.96 |
| CVS Health Corp. (CVS)vs › | $122.58B | 12.01 |
| Medtronic plc (MDT)vs › | $118.26B | 17.07 |
| Novo Nordisk A/S (NVO)vs › | $200.54B | N/A |
Trailing P/E
37.6
reported TTM EPS
Forward P/E
9.6
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.97 implies +290.8% EPS growth vs the reported trailing $0.76.
At today's $27.79 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.97 | $2.87 – $3.09 | 14 | 9.3x |
| 2027-12-31 | $2.89 | $2.77 – $3.10 | 14 | 9.6x |
| 2028-12-31 | $2.49 | $1.60 – $3.01 | 8 | 11.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
